Simon Moroney

Chairman at BIOTALYS NV

Net worth: 581 238 $ as of 2024-03-30

65 year

97 connections

Consumer Services

Health Technology

Government

Profile

Simon E.
Moroney was the founder of MorphoSys AG, a company founded in 1992, where he held the title of Chief Executive Officer from 1992 to 2019.
He is currently Vice Chairman at Novartis AG since 2020 and Chairman at Biotalys NV since 2021.
In his former positions, he served as Director-Supervisory Board at ProtAffin Biotechnologie AG from 2009 to 2011, and as President at the Government of Germany.
He also worked as a Research Associate at the University of Cambridge from 1991 to 1992, as an Assistant Professor at the University of British Columbia, as an Associate in the Chemistry Department at the Swiss Federal Institute of Technology from 1986 to 1989, and as an Associate at Harvard Medical School from 1984 to 1986.
Dr. Moroney obtained a doctorate degree from the University of Oxford in 1984 and a graduate degree from Waikato University in 1981.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
NOVARTIS AG 0.00%	2023-12-30	5,992 ( 0.00% )	581 238 $	2024-03-30

Simon Moroney active positions

Companies	Position	Start
NOVARTIS AG	Director/Board Member	2020-02-27
BIOTALYS NV	Chairman	2021-03-31

All active positions of Simon Moroney

Former positions of Simon Moroney

Companies	Position	End
MORPHOSYS AG	Chief Executive Officer	2019-08-31
ProtAffin Biotechnologie AG ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action.	Director/Board Member	2014-02-16
University of Cambridge	Corporate Officer/Principal	1991-12-31
Swiss Federal Institute of Technology	Corporate Officer/Principal	1988-12-31
Harvard Medical School	Corporate Officer/Principal	1985-12-31

See the detail of Simon Moroney's experience

Training of Simon Moroney

University of Oxford	Doctorate Degree
Waikato University	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Simon Moroney's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	3
NOVARTIS AG	Health Technology
MORPHOSYS AG	Health Technology
BIOTALYS NV	Process Industries

Private companies	2
Government of Germany	Government
ProtAffin Biotechnologie AG ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action.	Health Technology